Showing results (1-10 of 592) with videos related to
Sort By:
Pageof 60
Nature Reviews. Drug Discovery|January 1, 2013
Pharmacogenetic tests: the need for a level playing fieldMunir Pirmohamed, Dyfrig A HughesClinical Pharmacology and Therapeutics|November 23, 2018
Cost-Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation FrameworkCatrin O Plumpton, Munir Pirmohamed, Dyfrig A HughesBMJ (Clinical Research Ed.)|November 2, 2011
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analysesJoshua Pink, Steven Lane, Munir Pirmohamed, et al.Pharmacoeconomics|March 18, 2016
A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug ReactionsCatrin O Plumpton, Daniel Roberts, Munir Pirmohamed, et al.Rheumatology (Oxford, England)|September 29, 2017
Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for goutCatrin O Plumpton, Ana Alfirevic, Munir Pirmohamed, et al.BMJ Open|July 5, 2022
Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissionsRostam Osanlou, Lauren Walker, Dyfrig A Hughes, et al.Pharmacogenetics|July 13, 2004
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivityDyfrig A Hughes, F Javier Vilar, Charlotte C Ward, et al.Epilepsia|June 6, 2015
Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsyCatrin O Plumpton, Vincent L M Yip, Ana Alfirevic, et al.Pharmacogenomics|January 19, 2013
Adherence and variability in warfarin dose requirements: assessment in a prospective cohortAndrea L Jorgensen, Dyfrig A Hughes, Anita Hanson, et al.Journal of Personalized Medicine|July 1, 2018
Warfarin: The End or the End of One Size Fits All Therapy?Munir PirmohamedPageof 60